Payment overview · 2025
General Payments
$360.36
19 reported records · 13 companies
Healthcare provider profile · identity verified
William J Paronish, MD
Allopathic & Osteopathic Physicians|Family Medicine · NORTHERN CAMBRIA, PA · NPI 1104821057
Verified facts
What the public records show
CMS Open Payments records show William J Paronish, MD received $360.36 in general payments during 2025 across 19 reported records.
ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Synthroid by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 136 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $68.05 | 18.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $53.45 | 14.8% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $35.83 | 9.9% | 2 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $32.02 | 8.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24.80 | 6.9% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $22.08 | 6.1% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.92 | 6.1% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $20.51 | 5.7% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $20.07 | 5.6% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.55 | 4.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.53 | 4.6% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $13.89 | 3.9% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $13.66 | 3.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $360.36 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $68.05 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $53.45 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $35.83 | 2 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $32.02 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $24.80 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $22.08 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $21.92 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $20.51 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $20.07 | 1 | 2025 |
Source payment records
|
|||||
| GVOKE HYPOPEN Normalized: gvoke hypopen |
Drug | Xeris Pharmaceuticals, Inc. | $17.55 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $13.89 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
136 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 306 | 53 |
| Atorvastatin Calcium | Atorvastatin Calcium | 288 | 56 |
| Losartan Potassium | Losartan Potassium | 282 | 66 |
| Furosemide | Furosemide | 239 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 205 | 44 |
| Simvastatin | Simvastatin | 186 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 31 |
| Amlodipine Besylate | Amlodipine Besylate | 165 | 35 |
| Omeprazole | Omeprazole | 160 | 30 |
| Jardiance | Empagliflozin | 136 | 23 |
| Lisinopril | Lisinopril | 126 | 31 |
| Gabapentin | Gabapentin | 118 | 20 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 28 |
| Allopurinol | Allopurinol | 113 | 23 |
| Tramadol Hcl | Tramadol Hcl | 108 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 25 |
| Atenolol | Atenolol | 105 | 26 |
| Cephalexin | Cephalexin | 103 | 83 |
| Fluticasone Propionate | Fluticasone Propionate | 102 | 30 |
| Tamsulosin Hcl | Tamsulosin Hcl | 102 | 21 |
| Eliquis | Apixaban | 97 | 16 |
| Metformin Hcl Er | Metformin Hcl | 97 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 95 | 22 |
| Lorazepam | Lorazepam | 94 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 91 | 16 |
| Spironolactone | Spironolactone | 84 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 81 | 18 |
| Buspirone Hcl | Buspirone Hcl | 80 | 18 |
| Montelukast Sodium | Montelukast Sodium | 79 | 15 |
| Metformin Hcl | Metformin Hcl | 76 | 21 |
| Sertraline Hcl | Sertraline Hcl | 76 | 22 |
| Ezetimibe | Ezetimibe | 74 | 19 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 18 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 65 | 31 |
| Ibu | Ibuprofen | 65 | 15 |
| Trazodone Hcl | Trazodone Hcl | 64 | suppressed |
| Meloxicam | Meloxicam | 59 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 54 | 12 |
| Azithromycin | Azithromycin | 51 | 37 |
| Citalopram Hbr | Citalopram Hydrobromide | 50 | 12 |
| Donepezil Hcl | Donepezil Hcl | 50 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | suppressed |
| Potassium Chloride | Potassium Chloride | 46 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 46 | 11 |
| Farxiga | Dapagliflozin Propanediol | 45 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 45 | 13 |
| Valsartan | Valsartan | 45 | suppressed |
| Finasteride | Finasteride | 43 | suppressed |
| Myrbetriq | Mirabegron | 42 | 13 |
| Colchicine | Colchicine | 40 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 13 |
| Lansoprazole | Lansoprazole | 36 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 34 | suppressed |
| Ketoconazole | Ketoconazole | 34 | 11 |
| Famotidine | Famotidine | 33 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 33 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 23 |
| Primidone | Primidone | 28 | suppressed |
| Synthroid | Levothyroxine Sodium | 28 | suppressed |
| Ssd | Silver Sulfadiazine | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 26 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 26 | 14 |
| Celecoxib | Celecoxib | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Ibuprofen | Ibuprofen | 24 | 17 |
| Carvedilol | Carvedilol | 23 | suppressed |
| Novolog Flexpen | Insulin Aspart | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 22 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 22 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 21 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Xarelto | Rivaroxaban | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Alprazolam | Alprazolam | 19 | suppressed |
| Calcitriol | Calcitriol | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 18 | suppressed |
| Digoxin | Digoxin | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Novofine 32 | Pen Needle, Diabetic | 15 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 15 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 15 | 12 |
| Prednisone | Prednisone | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Anastrozole | Anastrozole | 13 | suppressed |
| Mesalamine Dr | Mesalamine | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 12 | suppressed |
| Butalb-Acetaminoph-Caff-Codein | Butalbit/Acetamin/Caff/Codeine | 12 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 12 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 12 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Methylprednisolone | Methylprednisolone | 12 | 12 |
| Mirabegron Er | Mirabegron | 12 | suppressed |
| Ranolazine Er | Ranolazine | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $360.36 · 19 records | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA, Cologuard Collection Kit, ENTRESTO, FREESTYLE LIBRE 3, GVOKE HYPOPEN, IBSRELA, LEQVIO, MOUNJARO, OTEZLA, Ohtuvayre, QULIPTA, REPATHA, UBRELVY, VOQUEZNA, XIFAXAN, ZEPBOUND | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error